Genetics of rare mesenchymal tumors: implications for targeted treatment in DFSP, ASPS, CCS, GCTB and PEComa

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Soft tissue and bone sarcomas are rare mesenchymal tumors with over 130 subtypes.
• Many sarcoma subtypes exhibit resistance to conventional chemotherapy, necessitating novel therapeutic strategies.
• Limited effective treatment options exist for many rare sarcoma diagnoses.

Purpose of the Study:

• To review the molecular underpinnings of targeted therapy for specific rare sarcoma subtypes.
• To highlight potential therapeutic targets in selected bone and soft tissue neoplasms.
• To provide insights into advancing treatment for rare cancers.

Main Methods:

• Literature review focusing on molecular alterations and targeted therapies.
• Analysis of targeted treatment implications for specific rare sarcomas.
• Discussion of current research and future directions in sarcoma therapy.

Main Results:

• Dermatofibrosarcoma protuberans (DFSP) shows promise with targeted agents like imatinib.
• Alveolar soft part sarcoma (ASPS) and clear cell sarcoma (CCS) present unique molecular targets.
• Giant cell tumor of bone (GCTB) and perivascular epithelioid cell neoplasms (PEComas) are being investigated for targeted interventions.

Conclusions:

• Targeted therapies represent a promising frontier for managing rare and chemoresistant sarcomas.
• Understanding the molecular landscape is crucial for developing effective treatments for subtypes like DFSP, ASPS, CCS, GCTB, and PEComas.
• Further research into molecular targets will improve outcomes for patients with rare bone and soft tissue tumors.